Drug Trial Radar · NCT01856218
An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
Last checked: Nov 20, 2026Latest source record: Jan 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3
Actual
Start
Nov 2013
Primary completion
Jul 2016
Study completion Jul 2016
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- May 17, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
UX003-CL201 is an open-label Phase 1/2 study to assess the safety, efficacy, and dose of UX003 in MPS 7 patients via intravenous (IV) administration every other week (QOW) for 36 weeks with up to an additional 36 weeks from the optional continuation period. Up to 5 participants, who are between 5 and 30 years of age inclusive, will be enrolled and treated with UX003. The initial 12-week treatment period will be followed by a 24-week forced dose titration period to assess the optimal dose. Participants who complete both the initial treatment and forced dose titration periods will continue treatment in a 36- week continuation period.
Conditions
- Mucopolysaccharidosis Type 7
Interventions
UX003Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change From Baseline in Urinary Glycosaminoglycan (uGAG) Dermatan SulfateTime frame: Baseline, Week 14, Week 22, Week 30, Week 38, Week 72, and end of study (up to Week 132)
- Percentage Change From Baseline in uGAG Chondroitin SulfateTime frame: Baseline, Week 14, Week 22, Week 30, Week 38, Week 72, and end of study (up to Week 132)
- Number of Participants With Any ≥ 50% Decrease in uGAGTime frame: up to Week 132
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and Study/Treatment DiscontinuationsTime frame: Up to 242 weeks + 30 days. SAEs were recorded beginning at the time the subject signed the informed consent form through 30 days following the last study visit. Non-serious AEs were recorded from the time of informed consent through the last study visit.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Manchester Academic Health Science Centre
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.